Glaucoma Research Foundation Web Site (Questions and Answers)

FDA’s Patient Network supports people who are looking for reliable information about medical products and their approvals, clinical trials, and other treatment options.

It is estimated that 5-15% of glaucoma patients, reportedly spending billions of dollars annually, take some form of alternative medication based only on their impression that it will help treat their glaucoma.

Glaucoma develops in some patients with a condition called exfoliation syndrome. Also known as pseudoexfoliation, it is caused by the abnormal accumulation of protein in the drainage system and other structures of the eye.

Glaucoma is a very misunderstood disease. Often, people don't realize the severity or who is affected.

How can we better diagnose or track the progression of glaucoma? The discovery of improved biomarkers for early detection or disease progression has the potential to radically change treatment of glaucoma.

Launched in 2002, the original team of four Catalyst for a Cure investigators has made a significant impact on the field of glaucoma research, helping to redefine our understanding of how glaucoma steals sight

Vision is our most prized sense, but to maintain healthy vision, we need to care for our eyes and have regular checkups.

A 20-page large-print booklet and a series of videos to help people adapt to life with low vision are available from the National Eye Institute (NEI), a part of the National Institutes of Health.

Dr. Gareth Howell was awarded the 2013 Shaffer Prize for Innovative Glaucoma Research for his study investigating the mechanism by which a spontaneous mutation prevents retinal ganglion cell death in glaucoma.

David Calkins, PhD, Catalyst for a Cure investigator and Vice Chair and Director of Research for the Vanderbilt Eye Institute, was recently awarded a Research to Prevent Blindness Senior Scientific Investigator Award.

Catalyst for a Cure is a unique approach to research developed by Glaucoma Research Foundation, which brings together scientists from different backgrounds to work collaboratively to understand glaucoma with the goal of finding a cure.

Glaucoma Research Foundation has expanded its novel initiative to advance glaucoma research through a collaborative approach by bringing together a second Catalyst for a Cure research team.

The first Catalyst for a Cure research team has worked together for 11 years to elucidate the molecular mechanisms of neurodegeneration in glaucoma and new therapeutic targets.

Glaucoma Research Foundation provides seed money for creative pilot research projects that hold promise. We consider it vital to invest funds in new high-impact research that may lead to major government and philanthropic support.

Glaucoma Research Foundation is marking World Glaucoma Week by announcing $1 million in grants for innovative glaucoma research awarded to a dozen investigators at prestigious institutions around the world.

Catalyst for a Cure is a unique approach to research developed by Glaucoma Research Foundation to accelerate the pace of discovery toward a cure for glaucoma.

The National Eye Institute observes Glaucoma Awareness Month each January by encouraging Americans at higher risk for glaucoma to schedule a comprehensive dilated eye exam.

Genetic factors are considered to play a key role in all major forms of glaucoma. In recent years the curtain that has blocked our view of the genetic cause of glaucoma has begun to lift, ushering in a new era in our understanding of the fundamental causes of glaucoma.

The visual field test is a subjective measure of central and peripheral vision, or "side vision" and is used by your doctor to diagnose, stage and follow your glaucoma.

GRF awarded Dr. Tonia Rex the 2012 Shaffer Prize for Innovative Glaucoma Research for her project investigating the effectiveness of a neuroprotective therapy in a model of inherited glaucoma.